Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
12 oct. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
28 sept. 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
11 août 2022 08h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
12 mai 2022 08h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
08 mars 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
27 oct. 2021 08h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
16 sept. 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
03 août 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
22 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
-Issued patent expands and strengthens Monopar’s existing camsirubicin IP portfolio-Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 WILMETTE,...
Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
18 févr. 2020 09h00 HE
|
Monopar Therapeutics Inc.
CHICAGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR) today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate...